Robert Lee, PhD, President, Lubrizol Life Science Health, CDMO Division, is responsible for product and business development along with providing strategic direction. Before joining Lubrizol, Dr Lee held senior management positions at Novavax, Lyotropic Therapeutics and Imcor Pharmaceutical Co. He holds BS degrees in Biology and Chemistry from the University of Washington, US, and a PhD in Physical Bioorganic Chemistry from the University of California, Santa Barbara, US. Dr Lee has published more than three dozen articles and five book chapters, as well as holding 11 issued patents and 15 provisional or PCT patent applications. He has over 30 years of experience in pharmaceutical research and development of both therapeutic drugs and diagnostic imaging agents. Dr Lee maintains strong academic ties, including an appointment as Adjunct Associate Professor of Pharmaceutical Chemistry at the University of Kansas, US, in the early 1990s, serving as a reviewer for both the International Journal of Pharmaceutics and Journal of Pharmaceutical Sciences, and serving on the Editorial Board for the Journal MOJ Bioequivalence & Bioavailability, The Scientific Pages of Nanotechnology and the Journal of Analytical and Pharmaceutical Research.
The CDMO Division of Lubrizol Life Science Health (LLS Health) is a leading pharmaceutical contract development and drug product manufacturing organization. With a range of technical capabilities, multiple technology platforms, and expertise in complex drug delivery, we can take on your formulation and production challenges.